Permeability Assay Platform Using KO Cells

Elevate your drug development process with Pharmaron’s specialized permeability assay platform, designed to precisely evaluate small molecule permeability and P-glycoprotein (P-gp) substrate properties. Using CRISPR/Cas9 technology, our MDCKII cell lines with targeted canine MDR1 knockout and transfected human, monkey, and mouse MDR1 genes provide accurate models for studying efflux activity and blood-brain barrier predictions.

Key takeaways from this poster include:

Advanced Cell Line Engineering: Leverage our canine MDR1-knockout and MDR1-transfected cell lines for reliable insights into efflux liability across species-specific P-gp.
Comprehensive Testing Capabilities: Evaluate compounds with our robust methodologies, including efflux ratio assessments and P-gp inhibition studies using PSC833.
Data-Driven Insights: Analyze transport mechanisms with detailed permeability and efflux data for compounds like propranolol, quinidine, and digoxin.

Pharmaron’s permeability assay platform ensures high-quality, reproducible data, enabling informed decisions for both early-stage screening and complex mechanistic studies.

Please complete the form below to download the poster:

Name (姓名)(Required)

First (名) Last (姓)

Company Name (公司名称)(Required)

Job Title (职位)(Required)

Country (国家)(Required)

State (州或省)(Required)

Message (留言 )

Email (邮件)(Required)

This field is hidden when viewing the form

Lead Source(Required)